IBG Risikokapitalfonds II GmbH & Co. KG
2
8M
2
1
- Areas of investment
Summary
Among the most popular fund investment industries, there are Biotechnology, Medical. Besides, a startup needs to be aged 1 and less years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Immunic
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the IBG Risikokapitalfonds II GmbH & Co. KG, startups are often financed by LifeCare Partners, bmp Ventures, Life Sciences Partners. The meaningful sponsors for the fund in investment in the same round are Omega Funds, Life Sciences Partners, LifeCare Partners. In the next rounds fund is usually obtained by German Federal Ministry of Education and Research (BMBF).
The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2017.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Exits
- 1
- Investments by industry
- Biotechnology (2)
- Medical (2)
- Life Science (1)
- Therapeutics (1)
- Energy Efficiency (1) Show 3 more
- Investments by region
-
- United States (1)
- United Kingdom (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Group Appearance index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Immunic | 05 Sep 2017 | Biotechnology, Medical, Life Science, Therapeutics | Early Stage Venture | 11M | United States, California, San Diego |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.